Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer
$11.5bn Acquisition Values Firm At A 34%-38% Premium
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.
You may also be interested in...
Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker
Assuming emergency use authorization of the antiviral to fight COVID-19 in December, Merck expects to make $500m-$1bn this year. It will share profits equally with partner Ridgeback.
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.